Health Ministry proposes 10 new import gateways for drugs, medical devices and cosmetics

The Health Ministry has proposed adding 10 ports of entry for imported drugs, medical devices and cosmetics through an amendment to Rule 43A of the Drugs Rules, 1945. The list includes inland container depots, a special economic zone and the Noida International Airport.

The Union Health Ministry has proposed adding 10 new points of entry through which drugs, medical devices and cosmetics may be imported into India. The change would be made by amending Rule 43A of the Drugs Rules, 1945, which specifies the ports and airports where such consignments can be brought into the country. The proposal has been put out for comment, allowing industry and the public to respond before a final decision.

The proposed locations include several inland container depots. These are at Sonipat, Piyala, Harsaru and Dadri in the north, Gandhidham and Mundra in Gujarat, Sanath Nagar and Thimmapur in Telangana, and Whitefield in Bengaluru. The list also includes the special economic zone at Bommasandra, near Bengaluru, and the Noida International Airport, which is expected to become a major cargo hub for the National Capital Region.

Rule 43A is significant because imported medicines and related products are regulated closely. Consignments must be cleared through designated entry points where drug control officials can inspect documents, verify licences and draw samples for testing. If a port is not on the list, importers cannot bring in regulated goods through it, which is why additions to the rule matter to traders and logistics firms.

Supporters of the move argue that expanding the list will reduce congestion at the existing gateways and cut the time and cost of moving goods inland. Many importers currently route consignments through a small number of major ports and then transport them hundreds of kilometres by road. Opening inland depots close to manufacturing and consumption centres could shorten that journey and improve the supply of time-sensitive products such as diagnostic equipment and temperature-controlled medicines.

The proposal also reflects the growing importance of medical devices in India's import basket. The country depends on foreign suppliers for a substantial share of its advanced equipment, from imaging systems to implants and diagnostic kits. At the same time, the government has been encouraging domestic manufacturing, and an efficient import system is seen as complementary because many local manufacturers rely on imported components and raw materials.

Regulators and public health experts, however, are likely to raise questions about capacity. Each new entry point needs trained drug inspectors, testing arrangements and reliable systems for tracking consignments. Adding locations without strengthening these functions could create gaps that allow substandard or unapproved products to enter the market. Concerns about counterfeit and poor-quality medicines are long-standing, and any expansion of gateways will be judged partly on whether oversight keeps pace.

Industry groups are expected to welcome the broader choice of entry points, while asking for clarity on procedures, timelines for inspection and the digital systems that will connect the new sites to central databases. Cosmetic importers, in particular, have in the past complained about delays caused by sampling and documentation requirements, and they will be watching how the revised rule is implemented.

The consultation period gives stakeholders an opportunity to raise these issues before the amendment is notified. Once the final rule is published, the more important test will be operational. The ministry will need to ensure that each site has the staff and facilities to function from the day it is added, so that the promise of faster clearance does not come at the expense of safety checks that protect patients and consumers.